BIOY.F Stock Overview
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
BioSyent Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$6.28 |
| 52 Week High | CA$6.97 |
| 52 Week Low | CA$5.26 |
| Beta | 0.93 |
| 1 Month Change | -2.18% |
| 3 Month Change | -1.72% |
| 1 Year Change | 7.50% |
| 3 Year Change | 2.78% |
| 5 Year Change | 12.75% |
| Change since IPO | 1,054.41% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOY.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.4% | -0.6% | 1.0% |
| 1Y | 7.5% | 10.6% | 21.9% |
Return vs Industry: BIOY.F underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: BIOY.F underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| BIOY.F volatility | |
|---|---|
| BIOY.F Average Weekly Movement | 2.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIOY.F has not had significant price volatility in the past 3 months.
Volatility Over Time: BIOY.F's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | René Goehrum | www.biosyent.com |
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
BioSyent Inc. Fundamentals Summary
| BIOY.F fundamental statistics | |
|---|---|
| Market cap | US$71.20m |
| Earnings (TTM) | US$4.72m |
| Revenue (TTM) | US$23.07m |
15.3x
P/E Ratio3.1x
P/S RatioIs BIOY.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOY.F income statement (TTM) | |
|---|---|
| Revenue | CA$31.59m |
| Cost of Revenue | CA$5.99m |
| Gross Profit | CA$25.60m |
| Other Expenses | CA$19.14m |
| Earnings | CA$6.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.56 |
| Gross Margin | 81.03% |
| Net Profit Margin | 20.45% |
| Debt/Equity Ratio | 0% |
How did BIOY.F perform over the long term?
See historical performance and comparison